Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice

Michael R. Verneris, Jeanette Baker, Matthias Edinger, Robert S. Negrin

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


Adoptive cellular therapy holds promise for improving the outcome of hematopoietic cell transplantation (HCT). At present, donor lymphocyte infusion post-HCT is efficacious for only a limited number of diseases, yet can induce significant graft versus host disease (GVHD). To improve the outcome of this approach, it would be beneficial to identify populations of T cells that retain graft versus tumor (GVT) effects with reduced propensity for GVHD. Here we describe studies of both human and murine expanded CIK cells or CD8+ NK-T cells. These related populations of cells are ex vivo activated and expanded T cells that express both T and NK markers. They can be generated from patients with malignancies and mediate cytotoxicity against autologous hematopoietic malignancies. Recent work in murine models show that these cells mediate cytotoxicity by using a perforin-granzyme and not through Fas ligand. In allogeneic stem cell transplantation experiments, large numbers of expanded CD8+ NK-T cells could be transplanted across major histocompatibility barriers without causing severe GVHD and GVT effects were retained. We conclude that expanded CD8+ NK-T cells are a promising form of cellular therapy in the allogeneic setting.

Original languageEnglish (US)
Pages (from-to)131-136
Number of pages6
JournalJournal of Clinical Immunology
Issue number3
StatePublished - Jun 17 2002


  • CD8 NK-T cells
  • CIK cells
  • GVHD
  • Immunotherapy

Fingerprint Dive into the research topics of 'Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice'. Together they form a unique fingerprint.

Cite this